Ascendis Pharma’s TransCon hGH Receives FDA Review for Adult Use

Ascendis Pharma ( (ASND) ) just unveiled an update.

Ascendis Pharma announced that the FDA has accepted their supplemental Biologics License Application for TransCon hGH in treating adult growth hormone deficiency. The decision marks a significant step in expanding the use of their already approved pediatric treatment, SKYTROFA, to adults, potentially enhancing their market position and offering new treatment options for adult patients.

More about Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies in endocrinology, oncology, and other therapeutic areas. Their primary products and services target complex medical conditions, with an emphasis on creating long-acting prodrug therapies using their proprietary TransCon technology.

YTD Price Performance: 6.61%

Average Trading Volume: 555,279

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $8.02B

For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.